Implantable Cardioverter Defibrillator Market is estimated to be US$ 13.6 billion by 2032 with a CAGR of 3.8% over the forecast period (2022-2032)

 


An Implantable Cardioverter Defibrillator is a battery-powered device placed under the skin that tracks the heart rate, thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat. An implantable cardioverter defibrillator is a small electronic device attached to the heart, used to continuously monitor and help regulate potentially rapid and life-threatening electrical problems with the heart. A transvenous or "conventional" ICD, shaped like a stopwatch, is implanted under the skin just below the collarbone, contains a pulse generator and wires, called leads. The pulse generator contain the battery and a tiny computer, one or more lead wires connect the pulse generator to specific locations in the heart. An ICD also records and stores an ICD that responds to irregular life-threatening heart rhythms in the lower chambers of the heart with a rapid pacemaker that corrects the rapid rhythm and increases the normal heart rate, or a shock that resets the heart rhythm to prevent sudden cardiac arrest. Information about heart rhythms and treatments delivered by physicians for review by ICD. An ICD can also be programmed to act as a primary pacemaker as needed.Sometimes after a shock, the heart can beat too slowly.The ICD has a "back-up" pacemaker, which can stimulate the heart to beat faster. As the normal heart rhythm returns, the ICD can act as a pacemaker if the heart rate falls below a predetermined rateSudden cardiac arrest is predicted to increase due to increasing number of patients suffering from cardiac diseases such as heart attack, abnormal heart rhythm, demand for implantable cardioverter defibrillators in the market and increase in certain risk factors such as smoking, sedentary lifestyle and obesity. Which is expanded to boost the demand for ICDs during the forecast period.

The report “Implantable Cardioverter Defibrillator Market, By Product Type (Implantable Cardioverter Defibrillator (Transvenous ICD, Subcutaneous ICD), External Cardioverter Defibrillator ( Manual External Defibrillator, Automated External Defibrillator, Wearable External Defibrillator )), End User (Hospitals & Clinics, Ambulatory Surgery Centers and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends,m Analysis and Forecast till 2030 “

Key Highlights:

·         In February 2022, Abbott announced the world's first patient implantation of a dual-chamber leadless pacemaker system as part of its AVEIR DR I2i pivotal clinical study. Implantation of Abbott's investigational Aveir dual-chamber leadless pacemaker is a significant technological milestone for leadless pacing technology and a worldwide first in a pivotal trial.

·         In August 2022, Medtronic plc, a global leader in healthcare technology, announced in August that its investigational EV ICD system achieved the first defibrillator defibrillation success rate of its kind with leads placed under the breastbone, outside the heart and veins. 98.7% and met its safety endpoint in a global clinical trial.

Analyst View:

ICDs are the mainstay of treatment for anyone who has survived a heart attack, ICDs are used in people at high risk of sudden cardiac arrest, and ICDs reduce the risk of sudden cardiac death more than medication alone. Cardiac defibrillators are important because they are used to prevent or correct arrhythmias, an irregular heartbeat that is too slow or too fast. Innovation in the Implantable Cardioverter Defibrillator market is increasing across the globe, owing to the technological advancements in the Implantable Cardioverter Defibrillator that are being used.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Implantable Cardioverter Defibrillator Market, By Product Type (Implantable Cardioverter Defibrillator (Transvenous ICD, Subcutaneous ICD), External Cardioverter Defibrillator ( Manual External Defibrillator, Automated External Defibrillator, Wearable External Defibrillator )), End User (Hospitals & Clinics, Ambulatory Surgery Centers and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/5008

ey Market Insights from the report:

Implantable Cardioverter Defibrillator Market accounted for US$ 10.3 billion in 2022 and is estimated to be US$ 13.6 billion by 2032 and is anticipated to register a CAGR of 3.8%. The Implantable Cardioverter Defibrillator Market is segmented based on Product Type, End User and Region.

·         Based on Product Type, Implantable Cardioverter Defibrillator Market is segmented into Implantable Cardioverter Defibrillator (Transvenous ICD, Subcutaneous ICD), External Cardioverter Defibrillator (Manual External Defibrillator, Automated External Defibrillator, Wearable External Defibrillator ).

·         Based on End User, Implantable Cardioverter Defibrillator Market is segmented into Hospitals & Clinics, Ambulatory Surgery Centers and Others.

·         By Region, the Implantable Cardioverter Defibrillator Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Implantable Cardioverter Defibrillator Market:

The prominent players operating in the Implantable Cardioverter Defibrillator Market includes, Medtronic, Boston Scientific Corporation, Biotronik, LivaNova Plc, Abbott, Microport, Koninklijke Philips N.V., Nihon Kohden Corporation, Progetti Srl, Fukuda Denshi Co., Ltd, Getinge, ZOLL Medical Corporation. The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

  1 860 531 2701

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

 

Comments

Post a Comment

Popular posts from this blog

Humanized Liver Mice Model Market is estimated to be US$ 133.72 billion by 2030 with a CAGR of 5.30% during the forecast period

Image
Humanized Liver Mice Model Market   accounted for US$ 78.64 million in 2020 and is estimated to be US$ 133.72 million by 2030 and is anticipated to register a CAGR of 5.30%.  A lot of studies are underway to create novel humanized liver mouse models. Initially, liver mice models were created by implanting human liver cells or hepatic cancer cells into basic immune-deficient mice. The results, however, were inconsistent and unreliable. As a result, immune-deficient mice were developed, which spontaneously destroy the mice liver, allowing human liver cells to proliferate and replace it, resulting in stable humanized liver mice models. For example, a number of research projects are looking into using PPARalfa and AFC8-based mice models to develop humanized liver mice models. The report "Global Humanized Liver Mice Model Market, By Model (uPA-SCID, FRG KO Mice, TK-NOG Mice  and Other Models) By Application (Pharmacokinetics Studies, In-vivo Liver Toxicity Testing, Drug Metabolism Stud
Read more

Bipolar Disorder Market is estimated to be US$ 6.7 billion by 2030 with a CAGR of 2.3% during the forecast period

Image
Bipolar Disorder Market   accounted for US$ 5.3 billion in 2020 and is estimated to be US$ 6.7 billion by 2030 and is anticipated to register a CAGR of 2.3%. Bipolar disorder known as manic depression is a mental illness that brings low moods and severe high moods, thinking, changes in sleep and have periods in which they feel overly happy and energized and other side feel very sad, hopeless and sluggish. Bipolar disorder can cause severe disruption to a person’s life which can be treated with appropriate treatment and support. The report "   Global Bipolar Disorder Market, By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs), By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), By Region (North
Read more

Monkeypox Disease Diagnostics Market - The abrupt global expansion of the monkeypox virus has increased the demand for monkeypox diagnostics.

Image
  The virus that causes smallpox and the Monkeypox both belong to the same family of viruses. Two outbreaks of a disease resembling the pox in groups of monkeys used for study led to the discovery of monkeypox in 1958. However, it has been observed in various parts of the world except Africa, where it is primarily found. It results in symptoms that resemble the flu, such as fever, chills, and a rash that might take weeks to go away. Even though instances of monkeypox are uncommon, they are growing in Africa and other areas where they have never before occurred. The fact that monkeypox is a rare disease may lead a healthcare provider to first rule out other rash infections, such measles or chickenpox. A tissue sample from an open sore is the first step in the medical professional's diagnosis of monkeypox (lesion). After that, send to a lab for PCR (Polymerase Chain Reaction). Additionally, blood is drawn to test for antibodies or the monkeypox virus. Currently, there is no licens
Read more